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D
uring the Boston Marathon on 15 April 2013,
two bombs exploded killing 3 people and injur-
ing 264 others. The bombs exploded just one and
a half days before the scheduled beginning of the ISEV
2013 Meeting. The leading news in world press was all
about the Boston explosions when over 700 scientists
of the extracellular vesicle field from all around the
world chose to go to the meeting. The ISEV 2013 meeting
was held as planned  a quiet triumph of science over
terrorism.
I. Opening of the meeting
Noting sympathy with all of Boston over the tragic recent
events, J. Lo ¨tvall, President of ISEV, F. Hochberg, Head
of the Local Organising Committee, and P. Quesenberry,
one of the Chief Editors of Journal of Extracellular
Vesicles (JEV), opened the second annual ISEV meeting
in Boston.
II. Oral sessions of the meeting
1. Biomarkers: urinary tract
In the past few years, urinary extracellular vesicles (EVs)
attracted substantial attention as non-invasive biomar-
kers. Beyond the proteomic composition, several authors
in Boston also presented data on the RNA patterns and
functionality of urinary EVs both in tumorous and non-
tumorous conditions. I. Bijnsdorp and colleagues (VU
University Medical Center, The Netherlands) identified
specific integrins in exosomes of prostate cancer cell lines.
She presented data that the exosomal integrins were
active and functioning as they facilitated the migration
and invasion capacity of non-cancerous prostate cells. A
significantly higher expression of exosomal integrins in
urinary exosomes was found in patients with metastatic
early-stage prostate cancer compared to benign prostate
hyperplasia or localised prostate cancer. The authors con-
cluded that exosomal integrins may play a role in pros-
tate cancer metastasis, and could serve as a basis for
risk stratification of prostate cancer metastasis. Next,
M. Jayachandran (Mayo Clinic, USA) discussed that litho-
genic molecules, such as oxalate and urinary crystals, may
induce renal cell activation that is reflected by the protein
composition of urinary vesicles. This finding broadens
the spectrum of diseases in which EVs may serve as bio-
markers to assess disease activity. In the next presenta-
tion, G. Deep (University of Colorado Denver, USA)
suggested a mechanism by which hypoxia may induce
a malignant phenotype in prostate cancer. Exosomes
secreted by a prostate cancer cell line under hypoxia (1%
O2) or normoxia (20% O2) were compared, and data were
presented that exosomes secreted during hypoxia were
loaded with unique signalling molecules and miRNAs
that may confer enhanced invasiveness to prostate cancer
cells. Focusing on another aspect of the question, C.
Belleanne ´e (Centre de Recherche du CHUQ/Universite ´
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unmet need for non-invasive biomarkers to diagnose
impaired sperm maturation. Seminal plasma EV miRNA
signatures from normospermic, vasectomised and vaso-
vasostomised donors were determined by microarray, and
compared to arrays with miRNA signature from human
epididymal tissues. The authors concluded that a specific
subset of seminal plasma EV-miRNAs was derived from
the epididymis, and may be used as non-invasive bio-
markers to diagnose male infertility cases related to
impaired sperm maturation.
2. EV biogenesis
More than 200 participants attended the session on
biogenesis of EVs. First M. Colombo (Institut Curie,
France) discussed results of an RNA interference screen
targeting individual components of the ESCRT machin-
ery in HeLa-CTIIA cells. She suggested a role of selected
ESCRT components in exosome secretion and composi-
tion by HeLa-CIITA cells, and a role for ALIX in co-
ordinating MHC Class II trafficking. She also provided
evidence for biogenetic differences in vesicles secreted by
different cell types. A presentation by H. Tahara followed
(Hiroshima University, Japan) who spoke about the secre-
tory mechanisms and functions of senescence-associated
exosomes. He noted that there is a high production of
exosomes in cellular senescence, and knock-down of
maspin by siRNA inhibits exosome production in pre-
senescent cells. Over-expression of maspin or CHMP4C
increases the number of exosomes by three-fold. P.
Zimmermann (Inserm-CRCM/K.U., France) described
syntenin as a rate-limiting factor for the recycling and
exosomal secretion of its cargo. She presented work on
the downstream effectors and upstream regulators of
‘‘syntenin exosomes’’ showing that a small GTPase,
ARF6, as well as a lipid-modifying enzyme, are involved
in the formation of intraluminal vesicles within multi-
vesicular endosomes. She mentioned that syntenin-ARF6
is at the intersection of endocytic recycling and the
exosomal pathway. M van Hoek (George Mason Uni-
versity, Fairfax, VA, USA) discussed the role of increased
membrane instability in higher outer membrane vesicle
production in Francisella tularensis. Among the factors
that increase membrane instability were mutations in the
TOL/PAL system which also caused increased biofilm
formation. She described the use of the outer membrane
vesicles from Francisella tularensis as a novel vaccine
candidate, based on positive results obtained with intra-
nasal vaccination of mice. Finally, A. Wehman (Rudolf-
Virchow-Zentrum, Germany) described the link between
the lipid flippase TAT-5 and EV budding. Large scale
shedding of EVs was observed with the loss of TAT-5
in C. elegans suggesting that the maintenance of lipid
asymmetry by flippases is important for the regulation of
EV budding. These results also suggest some shared
mechanisms with viral budding.
3. Parasites and fungi
It is well known that vesicles are secreted by a wide
variety of non-mammalian eukaryotes including uni- and
multi-cellular organisms, as well as both dedicated and
opportunistic pathogens. The first speaker of the session
was A.C. Torrecilhas (Universidad Federal de Sao Paulo,
Brazil) who presented work demonstrating a TLR2-
dependent immunomodulatory role of vesicles secreted
by Trypanosoma cruzi, which greatly enhances parasite
invasion of host cells both in vivo and in vitro. Changes
to the proteome of Leishmania infantum chagasi EVs
released during different lifecycle stages was presented by
B.K. Singh (University of Iowa, USA). M. Rodrigues
(Universidad Federal de Rio de Janeiro, Brazil) gave an
overview of EVs released by pathogenic fungi stressing
that the wide diversity of vesicles secreted is likely a result
of multiple mechanisms of cellular biogenesis. Proteins
functioning at different steps along the secretion pathway,
for example GRASP, SnF7p and Flippases, are all in-
volved to some degree in EV production. However, EVs
are still released by fungi when these proteins are
rendered dysfunctional by mutation, leading Rodrigues
to suggest vesiculation at the plasma membrane as at
least one alternative mechanism of vesicle biogenesis. In
support of this, using electron tomography of sequential
sections he showed that fungal plasma membrane reshap-
ing forms and releases vesicles directly into the extra-
cellular space. Following this discussion of EV biogenesis,
L. Nimrichter (Universidad Federal de Rio de Janeiro,
Brazil) showed that Candida albicans EVs are internalised
by dendritic cells and macrophages within 15 min. EV
treatment stimulated cytokine production and modu-
lated the antigen presenting phenotype of the cells. The
EVs bound to the cell GM1 prior to internalisation,
suggestive of a receptorligand interaction. Next, A.
Buck (University of Edinburgh, UK) discussed the small
RNA content of vesicles secreted by the gastrointestinal
nematode Heligmosomoides polygyrus. Several hundred
secreted pre-miRNAs were identified and stage specific
secretion was observed. Notably, some of the highly
abundant sequences were found to have the same seed
sites as mouse miRNAs involved with regulation of
immune responses. RNA-carrying EVs released by the
parasite were absorbed by the small intestine epithelial
cells of mice and worm-specific RNAs were internalised
by epithelial cells during co-culture with vesicles in vitro.
In conclusion, EVs secreted by diverse pathogenic
eukaryotes promote infection and invasion of host cells
and tissues via multiple mechanisms, similar to findings
with EVs from pathogenic prokaryotes. This suggests
that employing EVs as a pre-emptive attack on target
cells is an evolutionarily conserved pathogenic strategy.
Elena Aikawa et al.
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The session covered a wide-range of topics from foreign
body/tissue induced host responses, intercellular commu-
nication, and antigen presentation modalities. The ses-
sion was opened by D.M. Pegtel (VU University Medical
Center, The Netherlands) describing exosomal loading
and transfer of the RNA polymerase III-transcribed
small nuclear RNA EBER1 in inflammatory responses
associated with the Epstein-Barr virus. Exosomal transfer
of EBER1 (but not EBER2) is sufficient for inducing an
interferon-mediated inflammatory response within den-
dritic cells. Further, exosomes with EBER1 were detected
in sera of lupus patients, and EBER1 accumulation was
observed in renal epithelial cells. Interestingly, these cells
were found to be negative for Epstein-Barr virus DNA,
suggesting that EBER1 is transferred through the host
via exosomes in a manner that may be important for
innate immune responses to the latent virus. The session
continued with a talk by A. Morelli (University of
Pittsburgh, USA) describing the role of exosomes in
presenting donor MHC molecules to recipient dendritic
cells following cardiac transplantation. The current
paradigm of transplant recipient immune responses to
donor tissues involves transplanted dendritic cells of
donor origin that activate native responses. However,
few donor dendritic cells are often found in these tissues 
an observation that does not align with the large immune
responses often seen in transplant patients. In the study
presented, the authors demonstrated that exosomes con-
taining donor MHC molecules are accepted in clusters by
host recipient dendritic cells. Further, diptheria toxin
depletion of host dendritic cells in CD11c-diptheria toxin
receptor mice abolished T cell response to donor MHC
molecules. These data indicate that paracrine signalling
from native dendritic cells in the transplant recipient are
necessary for the host immune response to the donor
tissue, and may lead to a new paradigm of recipient
donor interactions in tissue transplantation. The session
then moved to therapeutic usage of monocytic-derived
exosomes loaded with the lipid a-galactosylceramide and
ovalbumin in directing inflammatory responses against
tumour growth. This study by S. Gabrielsson et al. from
the Karolinska Institute, Sweden demonstrated that
exosomal a-galactosylceramide and ovalbumin were
more potent in inducing active immunity compared
to soluble forms of these agents. Further, injection of
exosomes containing a-galactosylceramide and ovalbu-
min into an ovalbumin-specific melanoma mouse model
significantly increased survivability following tumour in-
duction. A. Cumpelik (University Hospital Basel, Basel,
Switzerland) followed with a presentation on the role of
neutrophil-derived ectosomes in controlling inflamma-
tory responses. The authors induced peritoneal inflam-
mation by injection of mono-sodium urate crystals into
the peritoneum of mice, and found a rapid release of the
pro-inflammatory cytokine IL-1b. This response was
quickly followed by the migration of neutrophils into
the peritoneum that reached a maximum accumulation
8 h after the initial injection. Injecting the mice with
neutrophil-derived ectosomes prior to the introduction of
the mono-sodium urate crystals led to lower levels of
IL-1b release and subsequent neutrophil migration. This
response could be mimicked using phosphatidyl serine,
but not phosphatidyl choline, liposomes. Further, endo-
genous neutrophil-ectosomes were found following neu-
trophil recruitment into the peritoneum. These results
suggest that these ectosomes may be part of an auto-
regulatory mechanism that is responsible for controlling
the degree of inflammatory responses. The lecture in
the Inflammation session given by D. Zecher (University
Hospital Basel, Switzerland) focused on the role of
microvesicles secreted by red blood cells during storage
and potential transfusion-related problems with aged
donor blood. The authors hypothesised that ectosomal
shedding by donor red blood cells during storage induces
systemic inflammation with the recipient. To test this
hypothesis, ectosomes purified from aged mouse red
blood cells were injected into recipient control mice of
mice primed with LPS. No effect was observed in the
control mice; however, mice primed with LPS and
injected with the ectosomes exhibited significant pulmon-
ary infiltration of neutrophils along with elevated levels
of IL-6. These effects were inhibited in C5a receptor defi-
cient mice, and the inflammatory responses in wild-type
mice were mitigated by thrombin inhibition. Similarly to
the findings in the previous lecture, the inflammatory
responses studied were recapitulated by injection of
phosphatidylserine liposomes. During the discussion
portion of the lecture, the presenter mentioned that re-
moval of ectosomes may be a strategy to prevent dele-
terious effects caused by aged donor blood. The final
lecture in the Inflammation session delivered by P.
Askenase (Yale University, USA) reported a novel means
of miRNA transport whereby exosome-free miRNA
associates with antigen-specific B cell exosomes to target
effector T cells. This extracellular association confers
antigen specificity to circulating miRNA, and these
results explain observations that miRNA-150 induces
immunosuppressive effects in an antigen-specific manner
in a model of murine contact sensitivity. Traditionally,
exosomal miRNA has been thought to exclusively origi-
nate from the exosomal source cell. Therefore, the results
presented may represent a dramatic shift in our under-
standing of the interactions of miRNA and exosomes.
5. Detection technology
Standardisation of pre-analytical variables remains a
major challenge in the analysis of EVs. R. Lacroix
(Marseille, France) discussed recent progress upon the
activity of the International Society on Thrombosis and
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Subcommittee in reducing inter-laboratory variation due
to sample preparation. Use of a common sample pre-
paration protocol reduced inter-laboratory variability of
flow cytometric enumeration of plasma EVs. J. Nolan (La
Jolla, USA) stated that artefacts and irreproducibility
represent the major obstacles to the use of EV measure-
ment in routine clinical practice. The small size and low
refractive index of EVs makes the analysis of small
vesicles very difficult. However, this may be partially
overcome by triggering on fluorescence rather than light
scatter. Using a newly developed nanoparticle flow
cytometer, optimised for analysis of individual membrane
vesicles, it is possible to obtain a 5- to 10-fold improve-
ment in fluorescence detection efficiency compared to
a commercial instrument. This theme was continued
by M.H.M. Wauben (Utrecht University, Netherlands),
who reminded us that ‘‘EVs are no cells’’ and that their
measurement requires a very different approach. Using a
fluorescence triggering based high-resolution approach, it
is possible to resolve nano-sized vesicles. However, it is
important to titrate the sample to avoid simultaneous
detection and measurement of multiple vesicles as a single
event. This so-called ‘‘swarm detection’’ resulted in an
underestimation of vesicle quantity and increased wide-
angle forward scatter and fluorescence signal. H. Im
(Massachusetts General Hospital, USA) described the
application of plasmonic nanohole arrays which use
surface plasmon resonance biosensors to study exosomes.
Up to 12 antibodies, in duplicate, were captured via
a PEG layer on a surface of a 24-hole nanoarray. The
nanoholes displayed a high sensitivity for exosome detec-
tion and facilitated the identification of unique biomar-
kers for ovarian cancer detection. The performance of
Nanoparticle Tracking Analysis (NTA) and Scanning Ion
Occlusion Sensing (SIOS) for the characterisation of
circulating EVs was discussed by S. Pedersen (Aalborg,
Denmark). Both methods showed acceptable degrees of
linearity and reproducibility. D. Kozak (Izon Science,
USA) continued on the theme of SIOS (also known as
tunable resistive pulse sensors [TRPS]), for size, concen-
tration and charge measurements of nanoparticles.
6. Glioma-derived EV
Glioblastoma (GBM), which is the most common
primary brain tumour derived from glial cells, is typically
rapidly fatal. GBM cells and other types of cancer release
EVs containing mRNA, microRNA, and proteins and
can be used in diagnostic applications. In fact, B. Carter
(University of California, USA) proposed the potential
use of exosomal EGFRvIII RNA in plasma and CSF as
a biomarker for GBM. M. Belting (Lund University,
Sweden) demonstrated that GBM-derived EVs were
rich in hypoxia-regulated mRNAs and proteins, repre-
sentative of the producing cell, several of which were
associated with poor prognosis. M. Sartori (University of
Padova, Italy) showed that GFAP/TF EVs were
increased in GBM patients, particularly after tumour
treatment, and that they correlated with disease progres-
sion. N. Atai (Harvard University/MGH, USA) showed
that cellular uptake of exosomes was decreased in the
presence of heparin, presumably because heparin medi-
ated exosome aggregation. The analysis of exosomes and
the determination of particle size, count, and components
are crucially important. R. Weissleder (Massachusetts
General Hospital, US) reported that a miniature nuclear
magnetic resonance (mNMR) technique enabled dif-
ferentiation of GBM-derived microvesicles from non-
tumour host cell-derived microvesicles. M. Morello
(Cedars-Sinai Medical Center, USA) presented his on-
going study on the characterisation of GBM cell-derived
large EVs, termed oncosomes. Electron microscopy
demonstrated that some oncosomes contained smaller
exosome-like particles in their luminal space, although
their biological significance has not yet been charac-
terised. These reports indicate that brain tumour EVs
may provide more reliable therapeutic avenues to treat
these malignant diseases.
7. Immune modulation
Earlier studies of S. Powis et al. (University of St
Andrews, UK) identified the presence of dimeric MHC
class I molecules on exosomes. In his presentation in
Boston, he presented data on the ability of HLA-A and
most HLA-B, but no HLA-C molecules to form dis-
ulphide-linked, dimeric structures on exosomes. G.E.R.
Grau (The University of Sydney, Australia) discussed
that human brain microvascular endothelial cell (HBEC)-
derived microparticles expressed MHC I, MHC II,
CD40 and ICOS. The vesicles enhanced T-cell activation
suggesting a novel role for microparticles in neuro-
immunological complications of infectious diseases. After
this presentation, J. Dalli (Brigham and Women’s Hospi-
tal and Harvard Medical School, USA) talked about lipid
mediator metabololipidomics data, and showed that
human neutrophil microparticles stimulate macrophage
efferocytosis and contribute to macrophage biosynthesis
of pro-resolving mediators during resolution of inflam-
mation. The next speaker was Sadallah (University
Hospital Basel, Switzerland) who showed earlier that
platelet-derived microparticles (ectosomes) had suppres-
sive activities on macrophages, DC and CD4 T cells. In
the presentation at the Boston meeting, evidences have
been summarised on the suppressive effects of platelet-
derived vesicles on NK cell functions also. The last three
presentations of the session included data obtained by
gene expression microarrays. M.M. Keber (National
Institute of Chemistry, Slovenia) has demonstrated that
partially oxidised phospholipids in microvesicles from
plasma of patients with RA or cells submitted to
Elena Aikawa et al.
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cells and in vivo. She discussed that hydro(pero)xyl phos-
pholipids in microvesicles represent a ubiquitous endo-
genous danger signal released under the oxidative stress,
which underlies the role of TLR4 signalling in inflam-
mation. N.P. Bretz (German Cancer Research Center
DKFZ, Germany) presented data on exosomes isolated
from body fluids such as amniotic fluid, urine, liver
cirrhosis ascites and malignant ascites from ovarian
carcinoma patients. Irrespective of the source, exosomes
triggered TLR-dependent signalling in THP-1 monocyte
cells that was abolished by pre-treatment with proteinase
K but not with DNase or RNase. The next speaker, T.G.
Szabo ´ (Semmelweis University, Hungary) provided evi-
dence that soluble mediators (cytokines/chemokines) that
arepresent simultaneously in the extracellular space along
with EVs, have a cross-talk. Thus, the effects of soluble
mediators in paracrine signalling may be substantially
modulated by EVs. The last speaker of the session, L.A.
Ortiz (EOH University of Pittsburgh, USA) presented
data that mesenchymal stem cells transfer mitochondria
and microRNAs by EVs as a mechanism for macrophage
regulation. Macrophage uptake of exosomes reduced
TLR expression and induced M1 polarisation.
8. Capture technology
Currently, the most widely used methods for EV isolation
include differential centrifugation and sucrose gradient
centrifugation. However, these methods are impaired by
the possible overlap between different EV populations
as well as protein complexes and other contaminants
pelleting together. In this session, alternative capturing
methods were presented which could circumvent some of
the limitations of current isolation methods. S. Stott
(Massachusetts General Hospital, USA) discussed the
development and application of a high-throughput micro-
fluidic chip designed for the isolation aswell as characteri-
sation of circulating tumour cells. The device was able to
increase the amount of interactions with antibodies
leading to an increased capture of these cells from blood.
H. Shao (Massachusetts General Hospital, USA) pre-
sented a microfluidic device able to capture circulating
glioblastoma multiforme microvesicles from volumes of
blood smaller than 1 mL. The device was able to dis-
tinguish between gliobastoma and normal host cell
derived microvesicles allowing for the identification of
EGFR, EGFRvIII and PDPN as markers of glioblastoma
derived microvesicles. The amount of these microvesicles
could be correlated to tumour size. K van der Vos
(Massachusetts General Hospital, USA) discussed a
microfluidic device designed with 8 channels in a herring
bone pattern and coated with antibodies against tumour
antigens to mediate EV capture. EV RNA was isolated
and analysed from the device. The following speaker,
T. Ichiki (University of Tokyo, Japan) presented work on
new methodology for single exosome analysis recording
the exosomes’ zeta-potential shifts after reacting with
anti-human CD63 antibody. The session continued with
the presentation of D. Rupert (Chalmers University of
Technology, Sweden) who discussed work on surface
plasmon resonance detection of exosomes. With this
method, low level of CD63 positive exosomes were de-
tected upon binding to abiotinylated anti-CD63 antibody
coated on a SPR gold chip. C. Helmbrecht (Particle
Metrix, Germany) discussed the difficulty of characteris-
ing the zeta potential of exosome preparations with
conventional methods due to their typically low concen-
tration. However, with a different method, the zeta
potential can be derived by measuring the electrokinetic
migration of exosomes in a microelectrophoretic device.
In addition, a laser and camera can be coupled to measure
exosomes’ light scattering as they move in solution,
allowing for the derivation of their size distribution using
the Einstein-Smoluchowski relationship. Next, M. Rous-
seau (University of Laval, Canada) discussed the effect of
secreted phospholipase A2 (sPLA2) on microvesicles. It
was observed that sPLA2 could degrade microvesicles in
biological fluids. Thus, it was recommended that studies
in which microvesicle levels are measured upon differ-
ent stimulations should also include measurements of
sPLA2 levels in order to account for their ability to
degrade microvesicles. Finally, S. Mathivanan (La Trobe
University, Australia) discussed work comparing differ-
ential ultracentrifugation, epithelial cell adhesion mole-
cule immunoaffinity pull down, and Opti-Prep
TM density
gradient. Isolation of exosomes from human blood
plasma was performed with the three methods and
revealed that Opti-Prep
TM density gradient was relatively
superior based on a lower amount of plasma proteins
found in the isolations.
9. Platelet derived EVs
The first speaker of the session was E.B. Boilard (Uni-
versite ´ Laval, Canada). Using an autoimmune arthritis
model and intravital imaging, he demonstrated that
platelets may promote the accumulation of microvesicles
outside the inflamed vasculature by stimulating the
formation of endothelial gaps. This effect was mediated
by platelet serotonin. This finding added to the rapidly
growing list of unexpected functions for platelets. Next
K. Witwer (Johns Hopkins University School of Medicine,
USA) introduced ISEV Consensus on procedures for
handling of biofluids for exosome analyses. He empha-
sised that as EVand exRNA research expands, important
questions about technical protocols, standards for speci-
men handling and appropriate normative controls have
been raised. In his talk, he outlined some of the con-
siderations recently summarised by the first ISEV Posi-
tion paper (Journal of Extracellular Vesicles 2013, 2:
20360). This presentation was followed by the lecture of
International Society for Extracellular Vesicles
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ted data on the prevention of artefactual in vitro platelet
vesiculation in acid-citrate dextrose (ACD) anticoagulant
tubes. He suggested the use of ACD tubes as antic-
oagulant tubes for subsequent flow cytometry analysis of
circulating EVs to preserve blood sample vesicle concen-
tration as close as possible to the in vivo conditions. Next,
A. Piccin (San Maurizio Regional Hospital, Italy) pre-
sented data on microparticles and vascular markers in
essential thrombocythaemia. The following speaker was
B. Laffont (CHUQ Research Center/CHUL, Canada)
who provided evidence for the presence of functional
Ago2microRNA complexes in platelet-derived micro-
particles that could exert extra-platelet mRNA regulatory
effects in recipient HUVEC cells. In the following pre-
sentation, C.C. Chen (Universityof California San Diego,
USA) discussed that the relative abundance of GADPH,
18S RNA, miR-103 and RNU49m in different cell
line-derived EVs were low, and varied by an order of
magnitude. Also, the authors found significant sample-to-
sample variation in glioblastoma patients. Therefore they
suggest that normalising EV content by the above genes
may arbitrarily bias the quantitative analysis of miRNAs.
L.H. Boudreau (Universite ´ Laval, Canada) showed that
neutrophils release inflammatory lipid mediators upon
incubation with platelet microparticle-associated immune
complexes (generated in vitro by co-incubating micropar-
ticles and anti-fibrinogen) in an Fc receptor-dependent
manner. The session was closed by the presentation of
T. Wurdinger (VUUniversity Medical Center, Netherlands)
who presented data on the uptake of tumour-specific
exosomes by platelets that contain mutated mRNA
transcripts. He showed evidence that platelets are useful
as a diagnostic platform for various types of cancer
patients.
10. Plenary session
J. Quackenbush (Dana-Farber Cancer Institute, USA)
gave a plenary lecture from the perspective of a computa-
tional biologist and genome scientist. He showed exam-
ples of alterations of proteinprotein interactions based
on microarray data, and emphasised applicability of
Bayesian statistics.
The next plenary lecture was given by S. Gould (The
Johns Hopkins University School of Medicine, USA).
In his presentation, he discussed that the biogenesis of
secreted vesicles can potentially occur at any organelle
of the exocytic and endocytic pathways. Using a cargo-
based approach, the relative contributions of these
organelles to the budding of both acylated and integral
membrane proteins were investigated. He presented data
that indicate that the plasma membrane is the primary
site of protein budding from animal cells, including hu-
man and fly cells.
Finally, A. Brisson (University of Bordeaux and IECB,
France) presented data obtained using cryo-transmission
electron microscopy (cryo-EM) imaging and receptor-
specific gold labelling. With this approach, he reported
the presence of three major types of EVs in normal
human platelet-free blood plasma: he described smaller
spherical objects (50500 nm) representing 80% of the
structures in blood plasma, tubular vesicles (15% of all
MVs) and large objects (up to 7 mm). Strikingly, he found
that only about 25% of vesicles bind Annexin V. He also
found that about 20% of platelet-free plasma micropar-
ticles expose CD41, while most large cell fragments derive
from red blood cells.
11. Prokaryote to eukaryote
D.Mulhall(UniversityofBritishColumbia,Canada)gave
a historical reviewof EV-related research, and encouraged
the audience to utilise and consider the 50 years of virus
research as directly relatable to the investigation of EV
biology. In addition to an overview of bacterial EVs,
Y.S. Gho (POSTECH, Korea) presented EVpedia (www.
evpedia.info), a high-throughput data collecting and min-
ing site dedicated to EVs (1), which curates proteomic,
lipidomic, and transcriptomic data from prokaryotes and
eukaryotes, enabling interspecies comparisons. Finally,
he discussed examples of the physiological relevance of
bacterial EVs; for example the induction of septic shock
by EVs alone (2), immune dysfunction in airways caused
by EV treatment (3), and EV-mediated non-inherited
b-lactam resistance in Staphylococcus aureus (4). T. Wei
(Southwest Baptist University, USA) demonstrated that
the production of EVs by Pseudomonas aeruginosa is
sensitive to changes in the extracellular environment,
including addition of antibiotics, and that vesicle release
is increased under antibiotic-induced SOS conditions.
Next, M. Sargiacomo (Instiuto Superiore di Sanita, Italy)
demonstrated that EVs produced by mammalian cells that
had been loaded with bacterial toxins (cholera toxin and
cytotoxic necrotising factor 1) in vitro propagated those
toxins from cell-to-cell, and did so in a more efficient
manner than treatment with toxins alone. His data show
that through EVs, a small population of cells can transfer
and amplify a signal to a much larger group of neighbour-
ing co-cultured cells, suggesting the technique could be
broadly applied to investigation of EV-mediated cellular
communication, endocrine function and homeostasis. The
session was closed by S. Biller (Massachusetts Institute
of Technology, USA) with a stimulating presentation
on the release of EVs by the marine cyanobacterium
Prochlorococcus. S. Biller showed that these organisms,
which account for approximately 10% of global photo-
synthesis, release 70100 nm vesicles  containing pro-
teins, DNA and RNA  at concentrations approximately
equal to the number of cells in the culture, 10
710
9 cells/
mL. This was also true in ocean water samples; upper
Elena Aikawa et al.
6
(page number not for citation purpose)
Citation: Journal of Extracellular Vesicles 2013, 2: 23070 - http://dx.doi.org/10.3402/jev.v2i0.23070regions of the ocean had EV concentrations at 6 million
vesicles/mL, similar to the number of bacteria, and this
concentration was reduced in relation to depth. Moreover,
EVs were found both in nutrient rich coastal waters and
nutrient poor open ocean environments. S. Biller put
forward three putative explanations for this massive
vesiculation: (1) EVs are avehicle for swapping of genetic
material including the potential of cross species DNA
sharing, (2) EVs provide defense against phages whereby
the vesicles act as dummy cells, and (3) EVs deliver a
source of fixed carbon to heterotrophic bacteria. S. Biller
left the audience with the titillating estimation that
potentially a full 10% of the earth’s organic carbon is
made up of extracellular vesicles in the oceans.
12. Heart and vessels
The lectures given in the Heart and Vessels session
touched on a variety of cardiovascular issues such as
angiogenesis, hyperlipidemia, calcification, and biomar-
kers for disease detection. The session was opened with a
talk given by S. Sahoo (Northwestern University, USA)
demonstrating hypoxia-induced changes in exosomal
miRNA from CD34 stem cells. A 2-dimensional electro-
phoresis analysis revealed few differences in protein
expression between normoxic and hypoxic exosomes;
however, miRNA analyses revealed that hypoxic exo-
somes were enriched in miRNAs-92a, 126, and 130a.
Introduction of an anti-miRNA-126 construct led to
reduced angiogenesis in an in vitro matrigel-based model
aswell as in an invivo mouse model of hind limb ischemia,
suggesting that miRNA-126 is necessary for angiogenesis
and neo-vascularisation. The second presentation of
the session, given by M.H. Nielsen (Aarhus University
Hospital/DanishPhDSchoolofMolecularMet.,Denmark),
identified a correlation between increased monocyte-
derived microparticles in a 30-patient cohort of famil-
ial hypercholesterolemia. Along with the association with
hyperlipidemia, the authors identified strong correlations
between monocytic microparticles, CD16 monocytes,
and intima-media thickness. These monocyte-derived
microparticles may be a measure of and participatory
in inflammatory responses to elevated oxLDL in in-
dividuals with familial hypercholesterolemia. In the
third lecture of the session, B.W.M. van Balkom (UMC
Utrecht, The Netherlands) presented evidence that
miRNA-214 is necessary for angiogenesis, endothelial
cell migration, and vessel sprouting using both in vitro and
in vivo models. Exosomal delivery of miRNA-214 to renal
endothelial cells inhibited expression of the protein ataxia
telangiectasia mutated, subsequently preventing senes-
cence in recipient cells. Therefore, the data indicate that
miRNA-2124 is crucial to the endothelial cell exosomal
responses that lead to angiogenesis. The fourth lecture
given by A. Kapustin (King’s College London, UK)
shifted the focus of the session to thebiogenesis of smooth
muscle cell-derived matrix vesicles that mediate vascular
calcification. The data indicate that matrix vesicles arise
from multivesicular bodies that form within vascular
smooth muscle cells. Matrix vesicle release was elevated
in synthetic non-contractile smooth muscle cells that arise
from culture in calcific conditions, and shedding of matrix
vesicles from these cells was abrogated by sphingomyeli-
nase inhibitionusing SMPD3. Further, SMPD3 treatment
suppressed calcification by smooth muscle cells in vitro.
Finally, matrix vesicles were found to contain the exoso-
mal markers CD63 and annexin A6, and both of these
markers were observed in histological sections of calcified
vascular tissue. Therefore, the data strongly indicate that
calcifying matrix vesicles are exosomal in origin, and are
produced by a phenotypic conversion of smooth muscle
cells to a non-contractile phenotype. The fifth lecture
of the session was delivered by D.P.W. de Kleijn (UMC
Utrecht, The Netherlands Interuniversity Cardiology
Institute of the Netherlands, The Netherlands, and
National University & National University Hospital,
Singapore). This study identified differential expression
of four marker proteins in plasma microvesicles from
patients that had a secondary cardiovascular event com-
pared to patients that had experiences of only a single
event. Of these markers, cystatin C, serpin F2, and CD14
MV levelswere associatedwith increased hazard ratios for
a secondary event. The results presented in this study
point to an important set of biomarkers that may help
identify those patients most at risk for secondary cardio-
vascular events. The final lecture in the heart and vessel
session was given by G.E.R. Grau (The University of
Sydney,Australia)andfocusedontheeffectsofmonocytic
microparticles on brain endothelial cell behaviour. In
an in vitro model of sepsis, THP-1 monocytes were treated
with LPS. This endotoxic activation led to enhanced
annexin V positive microparticle (between 100 and 1,000
nm) release from the cells. Further, confocal microscopy
indicated that these microparticles can be internalised by
hCMEC/D3 brain endothelial cells in a manner that is
blocked by inhibitors of endocytosis. Monocytic micro-
particles from LPS-activated THP-1 cells led to tighter
endothelial cell junctions, modified Src tyrosine kinase
phosphorylation, and enhanced endothelial cell micro-
particle production. These results indicate that micro-
particles from monocytes activated by endotoxin stimuli
may playa role in modulating endothelial cell responsesto
sepsis infection.
13. Isolation technology
Reproducible isolation and purification of EVs from cell
culture supernatants and body fluids remains a major
challenge. C. Maguire (Massachusetts General Hospital,
USA) described the use of heparin-agarose affinity
chromatography to purify EVs from conditioned media
from two cancer cell lines and HUVEC. The technique
International Society for Extracellular Vesicles
Citation: Journal of Extracellular Vesicles 2013, 2: 23070 - http://dx.doi.org/10.3402/jev.v2i0.23070 7
(page number not for citation purpose)resulted in a comparable yield to ultracentrifugation and
Exoquick
TM with improved purity. Y. Yoshioka (National
Cancer Center Research Institute, Japan) introduced
ExoScreen amplified luminescent proximity homoge-
neous assay based on the AlphaLISA technique. This
sensitive antibody capture based method enables the
detection and quantitation of specific subsets of EVs
having potential in cancer diagnostics. There have been
many recent developments in microfluidic devices for
EV isolation. N.V.J. Wise (University of Oxford, UK)
explained the technique of ‘‘magnetophoresis,’’ which util-
ises monoclonal antibodies conjugated to para-magnetic
beads in a continuous microfluidic system, and discussed
the features necessary for successful EV isolation. Another
microfluidic system using antibody-coated microbead
capture of EV was described by J. Rho (Massachusetts
General Hospital, USA). In this method, the isolated
EVs were labelled with target-specific magnetic micropar-
ticles, which were then detected by miniaturised nuclear
magnetic resonance. This facilitated antigenic profiling
of EVs shed from stored erythrocytes. Field flow fractio-
nation may be used to separate particles of different size,
and this technique has been applied to the study of
EV released from cancer cell lines by K. Agarwal (The
Ohio State University, USA). Further analysis of miRNA
showed that only a small number of secreted EV con-
tained miRNA. E. Zeringer (Life Technologies, USA)
reported on the latest commercially available techniques
for exosome isolation and analysis.
14. Stem cells
Mesenchymal stem cells offer great potential in therapy
for a wide range of conditions. Numerous data suggest
that EVs are key players in mediating the effects of
mesenchymal stem cells. In this session, the presentations
highlighted novel roles of EVs vesicles in the context of
stem cells. The session started with the lecture of S. Bruno
(University of Torino, Italy) who discussed work showing
that EVs derived from human mesenchymal stromal cells
inhibited in vitro tumour cell proliferation and survival as
well as the in vivo growth of established tumours. This pre-
sentation was followed by the lecture of P. Quesenberry
(Rhode Island Hospital/The Miriam Hospital, The
Warren Alpert Medical School of Brown University,
USA). He presented data on experiments where rat
lung derived EVs were able to induce epigenetic changes
in mouse bone marrow, as evidenced by the induction of
mRNA expression of surfactants A-D, aquaporin-5 as
well as clara-cell-specific protein. Next, J. Morhayim
(Erasmus University Medical Center, The Netherlands)
discussed work on the characterisation of osteoblast-
derived EVs and their effect and their interactions with
human umbilical cord blood CD34 haematopoietic
stem cells. Membrane and signalling proteins linked to
cell communication were found in osteoblast-derived EVs
and they were found to promote expansion of CD34-
expressing cells when incubated with CD34 UCB-
HSCs. The session continued with the presentation
of T. Lener (Paracelsus Medical University Salzburg,
Austria) who described the enhanced lineage induction of
bone-marrow-derived mesenchymal stem/progenitor cells
(BM-MSPCs) by exosomes derived from BM-MSPCs or
endothelial colony-forming cells (ECFCs). BM-MSPCs
derived exosomes promoted osteogenic and adipogenic
induction while ECFCs derived exosomes induced pro-
liferation. Next, L. Braccioli (University Medical Center
Utrecht, The Netherlands) presented work about the
role of mesenchymal stem cell (MSC) derived vesicles
in neuroregeneration. By developing a novel co-culture
system that allows for the exchange of soluble factors and
exosomes, between MSC and neural stem cells (NSC),
data were obtained showing that MSC vesicles could
mediate the differentiation of NSC towards the neuronal
and oligodendrocytic lineages. In the following pre-
sentation, S. Kiang (A*STAR Institute of Medical
Biology, Singapore) described the role of mesenchymal
stem cell (MSC) derived exosomes in mediating the effi-
cacy of MSCs against immune diseases. Her work showed
that MSC-derived exosomes have hypo-immunogenic
capacity. These exosomes activated monocytes and en-
hanced the production of regulatory T-cell (Treg). C.
Gardiner (University of Oxford, UK) described work on
the use of EVs to assess the quality of IVF embryos in an
attempt to determine those which are most likely to form
pregnancies after transfer to the mother. It was observed
that increasing EV size was strongly associated with
decreasing embryo quality and that, with further studies,
EVs may become a new parameter to determine IVF
embryo quality. Finally, S. Weilner (University of Natural
Resources and Life Sciences, Austria) discussed the effect
of EVs released by senescent endothelial cells on me-
senchymal stem cells. These EVs contained high levels of
miR-31 and reduced the osteogenic differentiation po-
tential of mesenchymal cells suggesting a possible role as
a diagnostic and therapeutic target.
15. Virus and prions
K.M. Pate (Johns Hopkins University School of Medi-
cine, USA) examined platelet activation and platelet
microparticle formation during acute infection in the
SIV-infected macaque model of HIV infection. She found
platelet activation during acute SIV infection accompa-
nied by increased platelet microparticle formation in
some macaques. The next speaker of the session was
T.C. Chen (Stanford University, USA) who discussed
regulation of HCV RNA and MIR-122 by RAB27A-
dependent exosome secretion pathway and showed that
viral replication complexes were excluded from exo-
somes. P. Leblanc (CNRS, France) investigated the role
of the components of the ESCRT machinery and the
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exosomal release of infectious prions. The presented data
suggested that prion accumulation within the cells can be
differentially affected by the ESCRTmachinery, and some
ESCRT components and the ceramide pathway can also
selectively inhibit exosomal release of prions. After this,
A. Narayanan (George Mason University, USA) demon-
strated the presence of TAR RNA in exosomes from
cell culture supernatants of HIV-1-infected cells. The
exosomes of HIV-infected cells contained host miRNA
machinery proteins, Dicer and Drosha and distinct cyto-
kines. Prior exposure of naı ¨ve cells to exosomes from
infected cells increased susceptibility of the recipient
cells to HIV-1 infection. Next, Gy Szabo (University of
Massachusetts Medical School, USA) presented abun-
dant data showing that exosomes in hepatitis C virus
infection mediate CD81-independent transmission and
are rich in Ago2-miR122-HSP90 complexes. Inhibiting
miR-122 or HSP-90 inhibitors were shown to suppress
exosomal transmission of HCV infection, suggesting their
potential use in anti-HCVimmune therapy resistant cases.
The session continued with the presentation of A. Hubert
(Universite ´ Laval, Canada) (HIV-1) who provided evi-
dence for elevated amounts of exosomes in antiretroviral-
naı ¨ve HIV-1-infected patients. These results indicate the
involvement of microvesicles in mediating cell death and
in the inflammatory response in HIV-1-infected subjects.
The next speaker of the session, A. Kotani (Tokai
University, Japan) provided evidences that EBV might
utilise the exosomal machinery to secrete key viral-
encoded miRNAs, through which EBV cells could
modulate the tumour microenvironment. Finally, M.J.
Kuehn (Duke University Medical Center, USA) referred
to previous work in their laboratory that has shown that
OMVs can bind the bacteriophage T4 irreversibly redu-
cing the infectivity of the T4. T4-OMV complexes were
found to represent a novel route of prophage induction
across bacterial species.
16. Proteomics
C.Jimenez (VUUniversityMedicalCenter,TheNetherlands)
started the session discussing mass-spectrometry data
obtained analysing 9 human cancer cell lines and 2 pri-
mary human cells comparing exosomes and the soluble
secretome. The exosome-enriched proteins were asso-
ciated with the ontology terms RNA post-transcriptional
modification, protein synthesis and cell signalling, tumour-
type-specific antigens and proteins belonging to on-
cogenic pathways. The next speaker was C. La ¨sser
(University of Gothenburg/Krefting Research Centre,
Sweden) who talked about using exclusion proteomics
and quantitative proteomics to identify immune-related
proteins in nasal exosomes. Exosomes were isolated
from pools of nasal fluid exosomes from healthy con-
trols, chronic rhinosinusitis (CRS) patients, asthma and
asthma/CRS. Molecules associated with asthma suscepti-
bility, such as mucins, were observed to be associated with
exosomes of the asthma groups. The immunoregulatory
S100 proteins were lower in the asthma/CRS patients.
The session continued with the lecture of S. Kreimer
(Barnett Institute of Chemical and Biological Analysis,
USA) who discussed the results of a pilot survey of
proteomic and posttranslational modification profiles
of extracellular microvesicles isolated from the media of
cultured MCF-7 and red blood cells, and blood plasma.
This was followed by the presentation of G.E. Reid
(Michigan State University, USA) who described signifi-
cant differences between the exosome lipid profiles and
their respective parent colorectal cancer cells, particularly
for alkyl ether-linked glycerophosphocholine, alkenyl
ether-linked glycerophosphoethanolamine and sphingo-
myelin lipids. Next, F. Dervin (Conway Institute of
Biomolecular & Biomedical Research, Ireland) described
that the platelet releasate, known to play a role in
atherosclerosis, comprises both soluble and exosomal
contents. Dervin quantified a panel of released proteins,
andforthe firsttime,releasedmiRNA,also.
D. Di Vizio (Cedars Sinai Medical Center, USA)
presented data obtained by the comparative proteomic
analysis of the shedded ‘‘large oncosomes’’ (110 mm) that
can be induced by over-expression of oncoproteins. She
demonstrated a 90% overlap between the proteomic
composition of large oncosomes and smaller size EVs,
however, found 79 proteins enriched in large oncosomes
(e.g. fibronectin) while canonical exosome markers were
enriched in small EVs in comparison with large onco-
somes. The session continued with the presentation of
D.S. Choi (Pohang University of Science and Technology,
Republic of Korea) who introduced data obtained by
label-free quantitative proteomic suggesting that cellular
proteins are specifically sorted into EVs. Vesicular pro-
teins are mainly derived from cytosol, cytoskeleton, endo-
some and plasma membrane rather than other cellular
compartments such as nucleus and mitochondria. En-
dosomal proteins and well-known vesicular marker pro-
teins including CD9, CD81 and 14-3-3 proteins were only
enriched in EVs. The last lecture was given by A. Lorico
(Roseman University of Health Sciences, USA) who
performed prominin-1-based immunomagnetic selection
in combination with filtration and ultracentrifugation
to isolate melanoma and colon carcinoma exosomes.
The study suggested that specific populations of cancer
exosomes contain multiple determinants of the metast-
atic potential of the cells from which they are derived
(including CD44, MAPK4K, GTP-binding proteins,
ADAM10 and Annexin A2). The authors found that
the exosomes showed a great enrichment in lyso-
phosphatidylcholine, lyso-phosphatidyl-ethanolamine and
sphingomyelin, and exposure of MSC to prominin-1-
exosomes increased their invasiveness.
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Among the speakers of the late breaking sessions, A.
Arakelyan (Kennedy Shriver National Institute of Child
Health and Human Development, USA) reported on the
flow cytometric analysis of individual microvesicles and
virions, using antibody capture on magnetic particles and
multicolour flow cytometry. This was used to characterise
EVs contained in HIV viral preparations and showed
differences in CD45, CD81 and CD63 expression between
EVs and virions. A novel assay platform using a mem-
brane capture technique was presented by M. Mitsuhashi
(Hitachi Chemical Research Center, Inc., Irvine, USA).
Following capture, EVs were lysed prior to poly(A) RNA
isolation, cDNA synthesis and gene amplification. J.
Smith (Nanosight, UK) then outlined improvements to
Nanoparticle Tracking Analysis software, which will lead
to improved accuracy of sizing and concentration mea-
surements of EVs. J. Costa (Laboratory of Glycobiology,
ITQB-UNL, Portugal) characterised glycoproteins and
glycans from exosomes of ovarian carcinoma cells using
lectin blotting, immunoblotting and mass spectrometry.
Costa and co-workers identified sialoglycoproteins en-
riched in exosomes. Distinct N-glycan profiles were also
found for exosomes that had higher levels of sialylated
glycans whereas the microsomal fraction was enriched
in high mannose glycans. M. Dams (University Clinic
Cologne, Germany) presented exciting evidence for the
existence of a tubular/vesicular network that might
contribute to tumour cell communication with distant
infiltrating immune cells to contribute to the proinflam-
matory Hodgkin lymphoma microenvironment. Accord-
ing to these data, EVs were released and guided by a
network of tumour cell-derived protrusions/cytonemes
and caused a polarisation of CD30L-positive recipient
cells. Z. Wang (The University of Texas at Austin, USA)
developed fabrication protocols for novel ciliated micro-
pillars (the micropillars with porous silicon nanowires
on the sidewalls) as a convenient microfluidic tool for
simultaneously multi-scale filtration of biofluids to iso-
late exosomes from complex biological samples. The
authors validated their microfluidic system using both
liposomes and biological fluids. Also among the late
breaking presentations, S. Montoro-Garcia (University of
Birmingham, UK) presented data on circulating small-
size microparticles as indicators of worsening status in
patients with systolic heart failure. K.R. Qazi (Karolinska
Institutet, Sweden) investigated the mechanism of action
of exosomes in sarcoidosis. More than 1500 distinct
proteins were identified on the BALF exosomes. The
expression of all the complement components was upre-
gulated in the exosomes from patients. Conversely,
CD55 and CD59 levels were higher in the exo-
somes from healthy controls. J.N. Leonard (Northwestern
University, USA) has developed a system for engineer-
ing exosomal membrane proteins that bind to defined
‘‘packaging’’ sequences within engineered RNA cargo
molecules. Using this engineered packaging system, the
authors could direct the incorporation of specific proteins
and RNA into exosomes. According to their data, there
are novel active sorting mechanisms and/or biophysical
constraints that dramatically modulate RNA loading into
exosomes.
17. Plenary session
R. Langer (Massachusetts Institute of Technology, USA)
opened the plenary session by focusing on the design of
systems for drug delivery as a template for exosome
studies. He emphasised that the critical problem for gene
therapy has been delivery. He quoted I. Verma as once
saying ‘‘the problem in gene therapy is delivery, delivery,
delivery.’’ R. Langer first discussed the barriers to effec-
tive delivery and the methods that have been developed so
far to address this critical problem. He noted that there
are three types of delivery: systemic, local, and targeted.
In the first two areas, he said there has been tremendous
progress, but in the third it is still very early. He noted that
two approaches (PLGA microspheres and PEGylation)
have proven very effective and are now widely used in
systemic delivery. In local delivery, stents, gliadel wafers
(for the brain), and ureter tubes have been able to deliver
high concentrations of drug to specific areas. With respect
to specific traditional barriers, he mentioned that the
transdermal barrier has been successfully hurdled by such
approaches as the nitroglycerin patch. In regard to the
lung, less than 2% of administered drug, such as from
nebulisers, typically reaches the organ. However, recent
studies have shown that the use of large porous aerosols
actually changes everything and succeeds in delivering
significantly more drug to the lung. R. Langer also
discussed approaches to overcoming the barriers to oral
delivery, mucosal delivery, and trans-vaginal delivery. In
closing, he discussed systemic RNAi delivery via lipo-
somes and noted that this approach is most effective in
organs that have a fenestrated epithelium (e.g. the liver,
spleen, bone marrow, and kidney). R. Langer’s lab has
developed a high-throughput combinatorial synthesis
approach to produce thousands of different lipids to use
in liposomes. R. Langer noted that there have been
‘‘remarkable potency improvements with novel lipid and
lipid-like materials over the past eight years.’’ All of this
work can provide useful paradigms for the study of
exosomes for drug delivery.
18. Plenary Session
R. Langer was followed by C D’Souza-Schorey (Uni-
versity of Notre Dame, USA) who described the biogen-
esis of tumour-derived microvesicles. She noted that
ARF6 is known to play multiple roles at the cell periphery
and in her work she has shown a direct correlation
between ARF6 activation and tumour progression. She
noted that ARF6 activation promotes the formation of
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stimulates the biogenesis of microvesicles that are en-
riched for the active form of ARF6. She noted that there
is selective sorting of cargo into the microvesicles and
VAMP-3 is required for cargo delivery to sites. Inhibition
of RAC-1 blocks the production of invadopodia and
massively promotes microvesicle shedding.
D. Lyden (Cornell University, USA) closed the session
by reporting on how tumour-derived exosomes promote
pre-metastatic niche formation and organotropism. He
emphasised that metastasis is an evolution and is not a
late process; rather, it starts being developed early in the
tumorigenic process. He said that secreted factors begin
laying the foundation of the pre-metastatic niche at sites
far removed from the primary tumour site very early.
These secreted factors include growth factors, chemo-
kines, hormones, extracellular matrix, microparticles and
exosomes, and cell-free nucleic acids. He said that the
tumour seems ‘‘to remember that I was once an embryo,’’
and seems to carry out reprogramming based on em-
bryonic memory. He noted that tumour-derived exo-
somes increase lung endothelial permeability, causing
vascular leakiness at this site. He added that melanoma-
derived exosomes induce fibronectin formation in pre-
metastatic niches. He reported examples of metastatic
organotropism with melanoma specifically targeting the
lung and liver and pancreatic cancer targeting the liver. In
the question period, Dr. Lyden said it might be possible
to re-direct tumour-derived exosomes to areas of the
body that are more accessible to surgery.
21. Nanoparticles
In his talk, R.M. Schiffelers (University Medical Center
Utrecht, The Netherlands) compared synthetic drug
delivery systems with EVs. He overviewed several aspects
including generation and loading of EVs with the desired
compounds, shelf-life and colloidal stability, tissue target-
ing, target cell interaction, delivery of cargo and read-
out of therapeutic effects. Next, P. Vader (University of
Oxford) introduced a piece of work in which exosomes
were isolated from HEK293T cells. Over-expression of
shLuc or let-7b in HEK293T cells led to increased
secretion via exosomes that were able to deliver the small
RNAs to tumour cells in vitro. In vivo biodistribution in
tumour-bearing mice showed accumulation of exosomes
in liver, spleen and tumour tissue. The following speaker
was D. Duelli (Rosalind Franklin University, USA) who
provided evidence that malignant transformation induced
de novo EVs, into which ex-miRs were assorted mutually
exclusively. Uptake of ex-miRs and its consequences were
cell-type and carrier-type specific. The presented data
may explain how ex-miRs can simultaneously activate
cancer-promoting cells and block anti-cancer cells. Later
during the session, D.Y. Jeong (POSTECH, Republic of
Korea) described the fabrication of exosome-mimetic
nanovesicles by extruding living cells through constric-
tive microchannels. These nanovesicles were suggested
to be used to study uptake and cellular material deli-
very pathway by EVs. This presentation was Y. Shu
(University of Kentucky, USA) who reported on the
fabrication of RNA nanoparticles with solid shapes,
resistant to RNase degradation. Importantly, upon sys-
temic injection, these RNA nanoparticles targeted cancer
exclusively in vivo without trapping in normal organs
and tissues. The presentation of K. Raemdonck (Ghent
University, Belgium) pointed out some of the most
unexpected findings of the meeting. The authors showed
electroporation of induced aggregation of siRNA leading
to overestimation of the efficacy of siRNA loading into
EVs. The authors electroporated Cy5-labelled siRNA.
Nanoparticle-tracking analysis (NTA) and confocal mi-
croscopy verified the emergence of large siRNA aggre-
gates, likely due to the electroporation-induced release of
aluminium cations from the cuvette electrodes. Thus,
electroporation-induced precipitation may strongly bias
the assumed encapsulation of siRNA into EVs. This pre-
sentation was followed by the one of A. Sehgal (Alnylam
Pharmaceuticals, USA) who have developed a non-
invasive method for following tissue-specific gene silen-
cing monitored in circulating RNA.
22. Biogenesis and targeting
The first speaker, H. Christianson (Lund University,
Sweden) provided evidence that heparan sulphate proteo-
glycans (HSPGs) function as internalising receptors of
cancer cell-derived exosomes, and the uptake was inhibi-
ted by exogenous heparin sulphate but not with chon-
droitin sulphate. The uptake was dependent on intact
HS 2-O-sulphation as well as N-sulphation. The lipid
raft associated protein caveolin-1 regulated the uptake of
exosomes negatively. The authors showed that exosome
uptake appears dependent on unperturbed ERK1/2-
HSP27 signalling, which is negatively influenced by
CAV1 during internalisation of exosomes. The second
speaker of the session, J.S. Lee (KAIST, Republic of
Korea) developed photoactive therapeutic exosomes pro-
duced by tumour cells treated with membrane fusogenic
liposomes loaded with therapeutic agents (photosensiti-
sers). C. Villarroya-Beltri (CNIC, Spain) identified short
RNA sequences over-represented in miRNAs enriched in
EVs. The session continued with the lecture of F. Verweij
(VUmc Cancer Center Amsterdam, The Netherlands)
who described that palmitoylation of the EBV oncopro-
tein LMP1 in exosomes may represent an interesting
analogous pathway to virion formation (during which in-
corporation in the budding virion of certain viral proteins
depend on palmitoylation). Next, F.A. Court (Catholic
University of Chile, Chile) proposed that exosomes
mediate macromolecular transfer between Schwann cell
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J.C. Gross (German Cancer Research Center, DKFZ,
Germany) showed that purified exosomes carry active
Wnt proteins on their surface and can induce Wnt
signalling activity in target cells. In the last presentation
of the session, L. Corrigan (University of Oxford, UK)
discussed data obtained using genetic tools in Drosophila.
An important physiological role was shown for exosomes
in seminal fluid, exosomes in sperm signalling and re-
programming female behaviour after mating, and the
presented work revealed the dynamics of exosome forma-
tion and secretion in vivo.
23. Multiomics
S. Montgomery (Stanford University, USA) launched the
Friday afternoon session on multiomics with a discus-
sion of the genetics of gene expression in exosomes. He
described his group’s study of a three-generation, 17-
member family for which every family member’s genome
had been sequenced and exosomal miRNA had been
obtained for each individual. mRNA and miRNA lib-
raries were created from cells and exosomes from family
members and sequenced using a HiSeq instrument. The
research team found a high correlation of exosomal
miRNAs among the individual family members, both in
cells and in exosomes. The team also found a huge
enrichment for certain miRNAs in the exosomes. Mon-
tgomery notedthat cell-specific regulatory variationcould
influence miRNA levels within exosomes. A. Clayton
(Cardiff University, UK) followed by describing the
quantitative proteomic analysis of cancer exosomes using
a novel modified aptamer-based array (SOMAscan
TM).
SOMA stands for Slow Off-Rate Modified Aptamers. In
using this approach to analyse the protein composition of
exosomes versus cells, he found these compositions to be
‘‘remarkably dissimilar,’’ in some cases varying by 200- to
300-fold. M. Kamali-Moghaddam (Uppsala University,
Sweden) discussed advanced tools for sensitive detection
of microvesicles and exosomes as biomarkers. He des-
cribed a proximity ligation assay (PLA) for the detection
of proteins and specifically reported on the use of a 4PLA-
based detection of prostasomes. He noted that prosta-
somes in blood plasma can reflect the aggressiveness of
prostate cancer. He also presented data demonstrating the
high sensitivity of a multiplex proximity extension assay
(PEA) for characterising prostasome surface proteins.
He asserted that PLA and PEA approaches are highly
specific, highly sensitive, and allow for multiplexing
without an increase in cross-reactivity. I. Kurochkin
(A*STAR, Singapore) reported that exosomes secreted
by human cells transport largely mRNA fragments that
are enriched in the 3’-untranslated regions. He noted that
exosomes contain a large number of mRNAs that can be
translated in anothercell. Generally, the exosomal mRNA
is smaller than the cellular mRNA, often being less than
500 nucleotides in length. He showed data indicating that
68.5% of mRNA in exosomes is fragmented. He also said
that the 3’ ends of transcripts contain elements regulating
stability, localisation, and translation activity of RNA.
J.M. Falcon-Perez (CIC bioGUNE, Spain) followed with
a talk on the application of omics-technologies to the
study of extracellular vesicles in order to identify candi-
date non-invasive biomarkers for liver injury. He noted
this is particularly important because of the difficulty of
obtaining liver biopsies. In EVs from hepatocytes, pro-
teomics analysis revealed 550 proteins; transcriptomics
revealed 1300 gene transcripts; and metabolomics showed
over 400 metabolites. He concluded that EVs are a
valuable resource for disease markers and that protein
candidates in serum could be useful in evaluating liver
injury. A. Vlassov (Life Technologies, USA) discussed
RNA profiling of exosomes. He initially described the
workflow he is currently using. This involves isolation of
exosomes, analysis, purification of RNA and protein, and
then analysis of RNA and protein. He noted that the
RNA cargo is primarily short RNA of 20200 nucleo-
tides. The cargo also includes some full-length mRNA
and ribosomal RNA, and little or no DNA. He empha-
sised that exosomes are not the only entities containing
extracellular circulating RNA. A significant fraction of
circulating miRNA is bound to proteins rather than
encapsulated in exosomes, he said. On average, each exo-
some contains 110 RNA molecules, he noted, assuming
an average length of 100 nucleotides. Vlassov works at
Life Technologies and he said that the company is plan-
ning to develop a complete arsenal of tools for exosome
and microvesicle research. G. Schmitz (University Hospi-
tal Regensburg, Germany) closed the session by reporting
that the multi-omics characterisation of subsets of platelet-
derived extracellular vesicles (PL-EVs) suggests their
involvement in the pathogenesis of vascular and neurolo-
gic diseases. He noted that PL-EV shedding increases
during platelet storage and platelet-derived EVs (PL-EVs)
are enriched in caveolin-1, ApoA-I/Fand clusterin, alpha-
synuclein, and contain amyloid precursor protein beta.
24. Plenary session
P. Sharp (Massachusetts Institute of Technology, USA),
co-winner of the 1993 Nobel Prize for Physiology or
Medicine for the discovery of RNA splicing, delivered a
lecture to a full house in this plenary session. He began
by noting that there has been an explosion in RNA
biology in the last 10 years, which has been fuelled in part
by advances that permit the sequencing of RNA at very
deep levels and by the increasing awareness of molecules
we previously did not even know existed. He emphasised
the importance of studying the kinetics of RNA delivery
to cells: what is delivered, how fast, and what happens
after delivery. He reported that we now know that
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siRNA and that the problem now is to translate this
knowledge into useful therapeutics. As also noted by
previous speakers, he said the critical problem is effective
delivery of the therapeutic molecules. He noted that
viruses solved this problem long ago. He said that
liponanoparticles containing siRNA have proven highly
efficient for specific gene silencing in hepatocytes. He
asked the question of how much siRNA is needed to
achieve gene silencing and reported that studies of factor
VII siRNA in a mouse model indicated that 1 ng of
siRNA per 1 gram of tissue was necessary and that this
corresponded to 100 molecules of siRNA per cell. This
would suggest, he said, that a single exosome would have
to carry 100 molecules of siRNA to achieve specific gene
silencing. He next suggested that a new modular approach
to therapeutic entities could speed the development
of new drugs and avoid the time-consuming problem of
always re-inventing the wheel. He gave the examples of
nanoparticle-drug, antibody-drug, lipid nanoparticles-
siRNA/miRNA, and conjugates with siRNA as useful
modules. He also reported the recent discovery of circular
RNA that can sponge up miRNAs and noted that a
decrease in regulation by miRNA is frequently observed
in cancer development. He described a dual reporter
technology that can be used to determine if there is
miRNA control in a cell and, if so, to what degree. In the
question section at the end of his talk, Sharp stressed the
importance of more kinetics and more quantitation in
RNA and exosome studies, and he closed by saying that
‘‘RNA biology is getting really interesting,’’ and empha-
sising that ‘‘nothing beats abiological assay, when you are
looking for a biological process.’’
25. Endocrine/exocrine
Starting the session, L.F. Lincz (Calvary Mater New-
castle Hospital, NSW, Australia) described that elevated
plasma levels of the fatty acid transporter, CD36, (mainly
on the surface of erythrocyte derived microparticles),
constitute a better biomarker for type 2 diabetes mellitus
than circulating CD36 protein concentration. The follow-
ing speaker, E. Buzas (Semmelweis University, Hungary)
summarised recent advances in our knowledge of the
roles of EVs in the induction, maintenance and regula-
tion of inflammation. She highlighted the significance
of the crosstalk between EVs and soluble mediators
(such as cytokines or chemokines) in the paracrine
signalling of cells. Next, S. Rome (CarMeN Laboratory
(INSERM1060/INRA1235), France) indicated that she
isolated and characterised mouse Quadriceps-released
exosomes under physiological conditions or during
insulin-resistance, and revealed that during insulin-
resistance, myotubes release exosome-like vesicles which
participate in functional alterations of pancreatic beta
cells. The next speaker, D. Burger (Kennedy Kidney
Research Centre, Canada) utilised a conditionally im-
mortalised human podocyte cell line (HPOD) as well as
two mouse models of progressive diabetic kidney disease.
As discussed, podocytes produce ectosomes which are re-
leased into urine and may be indicative of glomerular in-
jury. In her presentation, M. Frank Bertoncelj (University
Hospital Zurich, Switzerland) showed that extracellular
Poly (I:C) (PIC) associates with monocyte-derived micro-
vesicles (MVs) and is transferred to rheumatoid arthritis
synovial fibroblasts via MVs. The MV-delivered PIC may
preferentially activate certain cellular pathways resulting
in its pro-survival effects. Finally B. Bussolati (University
of Torino, Italy) whose presentation was originally
scheduled to Oral Session 1: Biomarkers: Urinary Tract,
discussed that markers of inflammatory cells of endothe-
lial damage and of cell regeneration can be detected in the
urinary microvesicles of transplanted patients.
26. RNA analysis
The session started with the presentation of J. Chung
(Massachusetts General Hospital, United States) who
developed a new lab-on-chip system that can selectively
enrich tumour-borne MVs and analyse their genetic
information. The new fluidic-based platform can perform
target-specific MV capture, their RNA extraction, and
on-chip RT-PCR, and may prove useful both in basic and
clinical research. The following speaker, R. Crescitelli
(University of Gothenburg, Sweden) determined RNA
profiles in exosomes, microvesicles and apoptotic bodies
isolated from the supernatant of three different cell lines
(HMC-1 human mast cell line, TF-1 erythroleukemia cell
line and BV2 mouse microglia cell line), using two dif-
ferent centrifugation-based protocols. She demonstrated
that the sub-populations of EVs have very different RNA
profiles and morphological characteristics. The session
continued with the lecture of ENM Nolte-’t Hoen
(Utrecht University, The Netherlands). She separated
EV sub-populations released during DC-T cell interac-
tions by buoyant velocity gradient ultracentrifugation.
Besides EVs that reach their equilibrium density of 1.15
g/mL after 14 h of ultracentrifugation (‘‘fast-floating
EV’’), a specific subset of RNA-containing EVs reached
this equilibrium density only after 60 h of ultracentrifu-
gation (‘‘slow-floating EV’’). The authors found that
during DC-T cell interactions, at least two different EV
sub-populations are released that differ in migration
velocity in density gradients, RNA content and morphol-
ogy. Next, H. Akiyama (Toray Industries, Inc., Japan) com-
pared the miRNA expression profiles of RNAs extracted
from: (a) EVs precipitated by ultra-centrifuging, (b)
precipitation of ExoQuick, (c) whole serum by QIAGEN
miRNeasy, and (d) whole serum by Toray 3D-GeneTM
RNA extraction reagent from liquid sample kit, and
compared the serum miRNA expression profiles detected
by: (a) ‘‘TaqMan’’ Array MicroRNA Card, (b) QIAGEN
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miRNA oligo chip. At the end of the session, D.
Gupta (University of ALLAHABAD, India) presen-
ted a computational approach for detecting candidate
motifs and clustering patterns in miRNAs derived from
exosomes.
27. Tissue injury
There was an impressive range of topics covered in the
session. Vesicles as non-invasive placental biopsies in
pregnancy were described by I. Sargent (University of
Oxford, UK) and studies in preeclampsia of vesicles
binding antibodies to cholera toxin recognising GM1
gangliosidesorAnnexinVrecognisingphosphatidylserine
showed elevations of preeclampsia related proteins and
might representbiomarkersforpreeclampsia(asdiscussed
by T.S. Sim (Institute of Medical Biology, Singapore)).
A numberof presentations addressed the question of vesi-
cle related tissue injury and recovery. Therewas a 68-fold
increase in plasmavesicle levels in sepsis associated kidney
injury (V. Cantaluppi, University of Turin, Italy). EVs
culturedwith kidney cells resulted in cell death, and blood
purification using citrate anticoagulants led to decreases
in plasma vesicle and cell injury. Vesicles from mesenchy-
mal stem cells promoted renal cell recovery after ischemic
injury (RS Lindoso; Carlos Chagas Filho Biophysics
Institute UFRJ, Brazil). miRNAs may be involved in
this process. Vesicles from endothelial progenitors also
accelerated glomerular healing in anti-Thy1.1 nephritis
through inhibiting complement injury and triggering
angiogenesis. Monocrotaline treatment of mice induces
pulmonary hypertension and vesicles from the plasma or
lungs of these mice could induce pulmonary hypertension
in normal mice (J. Aliotta; Rhode Island Hospital, USA).
28. Cancer: resistance and metastasis
Drug resistance is the most important cause of cancer
treatment failure for chemotherapy. EVs derived from
tumours have been found to enhance the development of
drug resistance. M. Bebawy (The University of Technol-
ogy Sydney, Australia) reported a novel cancer multi-
drug resistance (MDR) pathway mediated by EVs in vitro
and in vivo. EVs isolated from MDR breast cancer cell
lines contained P-glycoprotein (P-gp), which is a drug
efflux transporter protein, and functionally transferred
P-gp to drug-sensitive breast cancer cell lines. T. Patel
(Mayo Clinic, USA) reported that hepatocellular cancer
(HCC) increased the expression of long non-coding
RNA (lncRNA)-ROR in both cells and EVs compared to
non-malignant hepatocytes. They also demonstrated that
lncRNA-ROR in exosomes could modulate chemosen-
sivity in HCC. It is well known that metastasis is also
one of the hallmarks of malignancy progression and the
major cause of treatment failure in human cancer. J. Kim
(Cedars-Sinai Medical Center, USA) discussed potential
diagnostic marker proteins in tumour-derived EVs for
gefitinib-resistant non-small cell lung cancers (NSCLCs).
EVs derived from NSCLC increased cell proliferation
and invasion activity in recipient cells. Tumour-derived
EVs have also been implicated in facilitating not only the
development of drug resistance but also tumour invasion
and metastasis. Indeed, T. Arscott (NCI/NIH, USA)
showed the influence of radiation on EV secretion and
signalling in glioma cells. Interestingly, radiation in-
creased EV abundance and EV composition including
CFGF mRNA, miRNA, and IGFBP2 protein. In addi-
tion, take-up of EVs derived from irradiated cells was
increased, and they enhanced the migration and invasion
activity of recipient cells. Heparanase was found to
regulate secretion and function of tumour cell-derived
exosomes. Increased heparanase increased exosome se-
cretion, changed protein cargo, and stimulated spreading
of tumour cells on fibronectin and invasion of endothelial
cells (presented by C. Thompson, University of Alabama,
Birmingham, USA). V. Luga (University of Toronto,
Canada) demonstrated that fibroblast-secreted EVs pro-
moted human breast cancer cell protrusions, motility, and
metastasis via Wnt-planar cell polarity signalling. During
the poster session, T. Katsuda (NCRI, UK) reported that
osteosarcoma cells with knockdown of neutral sphingo-
myelinase 2 had decreased metastatic ability. However,
systemic administration of original cell-derived EVs
restored the metastatic ability of the knockdown cells.
These findings suggest that further characterisation of
EVs derived from tumours will lead to a better under-
standing of the appearance of drug resistance and
tumour metastatic properties, which may improve cancer
treatment.
29. Therapy: targeting and loading
The session began with M. Zo ¨ller’s (University Hospital
of Surgery, Germany) discussion of cancer immuno-
therapy and exosomes. She was followed by C. Lai
(Massachusetts General Hospital, USA) who described
the non-invasive in vivo imaging, tissue redistribution,
and clearance analysis of intravenously administered EVs.
V. Combes then spoke on unique roles for cytoplasmic
actin isoforms in mechanically regulating endothelial
microparticle formation. Next, M. Pegtel (VUmc, The
Netherlands) describedhowcomprehensivedeep sequenc-
ing analysis revealed non-random small RNA incorpora-
tion into tumour exosomes and discussed the biomarker
potential of these results. S. Kooijmans (University
Medical Center Utrecht, The Netherlands) closed the
session by speaking on how the loading of siRNA into
EVs is accompanied by extensive siRNA aggregate
formation.
30. Neurodegeneration
Several talks highlighted the role of EVs in neurodegen-
eration. First, G van Niel (Institut Curie/CNRS, France)
described the presence of multilayer structures on the
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oligomers in cryo-EM images. Further, van Niel reported
that formation of these structures correlates with the
presence and the processing of amyloidogenic domains
of PMEL. Next, L. Rajendran (University of Zurich,
Switzerland) proposed that exosomes are a major way to
shuttle cytosolic proteins and amyloids out of the cell.
Release of b-amyloid (Ab) peptides on exosomes aids in
the plaque formation. C. Verderio (CNR Institute of
Neuroscience, Italy) reported high production microglia-
derived MVs in Alzheimer disease patients, and that MVs
enhance Ab1-42 toxicity, thus providing a new link
between microgliosis and AD degeneration. The session
continued with the presentation by A. Cooper (Garvan
Institute of Medical Research, Australia) who discussed
the role of exosomes in Parkinson’s disease proposing
that extracellular transmission of toxic alpha-synuclein
aggregates between neurons may serve as a basis for the
neurodegenerative progression of Parkinson’s disease.
Cooper and co-workers discovered a protein whose
expression level can modulate the extent of externalised
alpha-synuclein associated with exosomes, potentially by
influencing exosome biogenesis. The next speaker, A. Hill
(University of Melbourne, Australia) reported that in-
fectious prions were associated with intact, morphologi-
cally distinct exosomes. Hill and his co-workers found
indication that intact vesicles are required for the
successful transfer of prion infection. The RNA content
of vesicles also demonstrated alterations in the levels of
specific miRNA profiles between control and infected
cells. The last speaker of the session, J. Skog (Exosome
Diagnostics Inc., USA) reported the use of a platform
to reproducibly extract high-quality CSF microvesicle
RNA for RNA profiling from frozen biobanked CSF. He
found a general down-regulation of the miRNAs in the
Alzheimer patients and dysregulation of several miRNAs
suggesting that CSF microvesicle RNA may be useful for
the diagnosis of Alzheimer’s disease.
31. Cancer: cellcell communication
Cellcell communication is an important tool for organ-
isms and can be regulated through direct cell-to-cell
contact, transfer of secreted molecules, or transfer of
EVs. Recently, many reports have shown that EVs can be
transferred between cells and that the contents of EVs,
including protein, DNA, mRNA, and miRNA, are
functional in recipient cells. D. Holterman (Caris Life
Sciences, USA) demonstrated that the amount of exoso-
mal miRNA in plasma was generally 5-fold higher in
cancer patients than in healthy donors. E.A. Chiocca
(Brigham and Women’s Hospital, Harvard Medical
School, USA) showed that exosomal miR-1, which is
expressed at low levels in glioma, could inhibit angiogen-
esis through the down regulation of ANXA2 expression in
recipient cells. H. Peinado (Weill Cornell Medical College,
USA) reported that EVs derived from melanomas pro-
mote the metastatic behaviour of primary tumours
by permanently ‘‘educating’’ bone marrow progenitors
through the receptor tyrosine kinase MET. Moreover,
they also demonstrated that the amount of exosomal
TYRP2, which is a melanoma-specific gene, was signifi-
cantly increased in melanoma patients’ plasma. J. Kim
(Cedars-Sinai Medical Center, USA) revealed that EVs
derived from DIAPH3-knockdown prostate cancer cells
promoted cell proliferation and invasive activity in
recipient cells and suppressed the proliferation of human
immune cells. Several presentations focused on oncogene
transfer using EVs. R. Simpson (La Trobe University)
reported that EVs from oncogenic H-Ras over-expressing
canine kidney cells induced EMT and the release of
factors linked to promoting the metastatic niche, includ-
ing transcription/splicing factors, in recipient cells. T. Lee
(Montreal Children’s Hospital Research Institute, Canada)
presented data showing that ‘‘oncosomes’’ containing
both mutant H-Ras protein and DNA could mediate the
transfer of this oncogene into susceptible normal fibro-
blast cells, leading to long-term transformation (at least 7
days). It was also noted that stromal cell-derived EVs
could inhibit tumour growth and malignancies. S. Bruno
(University of Torino, Italy) reported that EVs from
human mesenchymal stromal cells could inhibit tumour
growth and survival in vitro and in vivo. Collectively, these
reports demonstrate that the tumour microenvironment
regulates malignant properties by eliciting reversible
changes in the phenotype of cancer cells via EVs.
32. Therapy-stem cells
The first lecture on therapeutic aspectsofstem cell derived
EVs focused on their role in graft-versus-host disease
(GVHD). L. Kordelas and colleagues (University Hospi-
tal Essen, Germany) reported a case-study regarding a
successful therapeutic intervention with mesenchymal
stem cell derived exosomes in therapy-refractory acute
GVHD. Bone marrow derived stem cells were obtained
from four independent donors. Immunosuppressive ef-
fects of exosome preparations were compared in vitro and
the one exerting the most prominent effect was selected
for therapeutic administration. The patient, a 22-year old
female with therapy-refractory cutaneous and intestinal
GVHD Grade 4, tolerated subsequent doses well and her
symptoms improved significantly. In this case, MSC
derived exosomes appeared to be a safe and effective
therapeutic option for therapy-refractory GVHD. Moti-
vated by the potential in EVs for specific and effective
drug delivery, S.C. Jang and colleagues (Pohang Uni-
versity of Science and Technology, Republic of Korea),
have described a new approach to generate artificial
vesicles that mimic the features of exosomes. These bio-
inspiredvesicleswere generated by the extrusion of mono-
cytic cells through polycarbonate membranes. Cargo was
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process. Delivery of cargo loaded into artificial vesicles
during the extrusion process, was demonstrated invarious
models, including mouse tumour models for testing
chemotherapeutics. Artificial vesicles described in the
lecture, were not only found to be efficient for targeted
delivery, but their yield has also been shown to be orders
of magnitude greater than possible yields for exosomes.
The potential therapeutic application of EVs of a geneti-
cally modified cell line was demonstrated by Z. Cai and
colleagues (Zhejiang University, China). In the myelin
oligodendrocyte glycoprotein (MOG) peptide-induced
murine experimental autoimmune encephalomyelitis
(EAE) model, the exosomes of membrane-associated
TGF-ß1 gene-modified dendritic cells (mTGF-ß1-EXO)
were found to prevent both the development and the
progression of the disease. In the presence of mTGF-ß1-
EXO, the level of cytokines associatedwith Th1 and Th17
immune responses decreased, in contrast to enhanced
IL-10 production and increased numbers of Treg cells.
Furthermore, this immunosuppressive effect was not
abrogated, even when mTGF-ß1-EXO of C57BL/6 mice
were administered to another murine strain, Balb/c.
The factors secreted by stem cells seem to be at least
as important as the cells themselves in therapy and one
of the factors secreted by MSC is EVs. R.C. Lai and
colleagues (Institute of Medical Biology, Singapore) were
focusing on how these structures can exert their effect.
Exosomal cargo was analysed by mass spectrometry in
order to identify biochemical reactions potentially modu-
lated by exosomal proteins. Key functions predicted to be
affected, included glycolysis, activation of kinase path-
ways, reducing complement activation and increasing
proteasome function. Modulation of the predicted bio-
logical functions was also confirmed by the appropriate
enzymatic or cellular assays.
How cell differentiation and survival might also be
affected by the presence of EVs in vitro, was demonstrated
by R. Andriantsitohaina and colleagues (INSERM,
France). Administering microparticles of activated or
apoptotic lymphocytes to human umbilical vein endothe-
lial cells resulted in a pro-angiogenic and anti-apoptotic
effect. Scavenging reactive oxygen species and carrying
antioxidant enzymes might be an important factor in the
anti-apoptotic effects of EVs. Both pro-angiogenic and
anti-apoptotic effects were abolished however, in the
presence of a pharmacological inhibitor of Sonic Hedge-
hog signalling, cyclopamine. In contrast to the previous
report on anti-apoptotic effects, V. Huber and colleagues
(Fondazione IRCCS Istituto Nazionale dei Tumori, Italy)
propose an anti-tumour strategy based on modified EVs
inducing apoptosis. The apoptotic signal TRAIL was
expressed by the K562 cell line in a membrane-bound
form and also detected in exosomes secreted by these cells.
The proapoptotic effect of TRAIL containing exosomes
could be demonstrated in vitro on haematological cancer
and melanoma cell lines, but only a moderate effect was
observed in vivo on tumour progression.
33. Bacteria-infection
E. Ligeti (Semmelweis University, Hungary) launched the
session on bacteria and infection by showing data
demonstrating that neutrophil-derived anti-bacterial mi-
crovesicles are increased in bacteremic patients. Next, F.
Vazirisani (University of Gothenburg, Sweden) discussed
the effect of membrane vesicles from Staphylococcus
aureus and Staphylococcus epidermidis on monocytes
and macrophages. R. Ovstebo (Oslo University Hospital,
Norway) then reported that the inhibition of complement
protein 5 reduces Neisseria meningitidis-induced micro-
particle-associated tissue factor activity as measured by
thromboelastography in whole blood. J. Schorey (Uni-
versity of Notre Dame, USA) described the characterisa-
tion of exosomal RNA from M. tuberculosis-infected
macrophages and discussed the potential use of these
RNAs as molecular biomarkers for tuberculosis. Finally,
Y. Cheng (University of Notre Dame, USA) reported
that exosomes containing mycobacterial antigens induce
a protective immune response against M. tuberculosis
infection in mice.
III. Poster presentations
This report cannot undertake the task to individually
discuss the 243 posters presented in Boston. Therefore,
here we will refer to a limited number of important
posters with special focus on those awarded as out-
standing posters by the ISEV Award Board.
An interesting poster demonstrated that E. coli-derived
vesicles were found to induce emphysema via both IFN-
gamma and IL-17 dependent pathways and vesicles from
activated fibroblasts enhance fibrosis in a Bleomycin lung
injury model (J.-P. Cho, POSTECH, Republic of Korea).
In neural studies, neuronal exosomes were shown
to eliminate Alzheimer’s amyloid protein (K. Yuyama,
Hokkaido University, Japan). These results suggest that
amyloid-b protein binds and assembles on the surface of
exosomes and is delivered into microglia to degrade
together with exosomes. In a similar vein, exosomal
mediated release of alpha-synuclein had implications for
Parkinson’s disease (G. Thakur, University of Zurich,
Switzerland). Furthermore, endothelial ectosomes were
found to be elevated in a rodent model of cerebral
hypoperfusion (D. Burger, University of Ottawa, Canada).
These particles cause apoptosis in cultured cells and a
decrease in blood brain barrier permeability in vivo.
Endothelial cell-derived microparticles were also found
to exert catabolic effects on intervertebral discs (P.H.I.
Pohl, University of Pittsburgh Medical Center/The
Ferguson Lab For Or, USA).
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detrimental effects of vesicles on cancer. Breast tumour-
derived vesicles enhanced EMMPRIN-dependent human
breast cancer invasion (K. Menck, University Medical
Center Gottingen, Germany). Breast and melanoma
derivedvesicleswere found to directly influence metastatic
sites in the lung and to modulate marrow cells to fur-
ther influence metastases (T.-L. Shen, National Taiwan
University, Taiwan). Exosomes from brain metastases
breast cancer cell were also shown to promote the blood
brain barrier destruction (N. Tominaga, National Cancer
Center Research Institute, Japan).
There were also a number of posters related to prostate
cancer. There was reversal of resistance of prostate cancer
cells to campothecin and anchorage independent growth
in soft agar by vesicles from a normal prostate cell line
(K. Panagopoulos, Rhode Island Hospital, USA). Con-
versely, prostate cancer exosomes could promote prostate
cancer progression via activation of ERK cell pathway
(E.H. Beheshti, The Vancouver Prostate Centre (UBC),
Canada). Of interest was a report showing that epithelial
mesenchymal transition could be induced in normal
prostate cell lines by MVs from a T cell line (Jurkat)
(J.M. Inal, London Metropolitan University, UK).
Gist exosomes mediated transformation and had a role
in tumour spread while microparticle-mediated transfer
of ABC drug resistance was shown and an association
of exosome secretion and drug resistance in aggres-
sive B-cell lymphomas (S. Atay, University of Kansas
Medical Center, USA) was demonstrated. Diminished
exosome release was associated with increased efficacy of
imunochemotherapy.
Melanoma cell derived exosomes re-educate mesench-
ymal stem cells through their miRNA cargo giving rise
to a population that supports metastases (M. Harmati,
Hungarian Academy of Sciences, Biological Research
Centre, Hungary).
Regarding the biogenesis of EVs, V. Hyenne and
colleagues (IGBMC, France) focused on the intracellular
mechanisms involved in trafficking exosome-containing
MVBs to the plasma membrane. Studying exosome
biogenesis in C. elegans, the authors could exploit the
advantages of studying a multicellular organism with live
imaging techniques, as well as molecular genetics. Based
on their previous observation that EVs contribute to alae
formation (part of the cuticle), RNAi screening yielded
over candidate 60 genes. Confirming subsequent changes
in MVB morphology by EM, the exocyst protein complex
and its regulator, ral-1 were found to be important in the
mechanism of exosome release.
Innovative approaches for isolation and detection of
EVs were presented by many posters at the meeting.
Among these attractive posters, R. Baek’s (Aalborg
University Hospital, Denmark) approach has engaged
an outstanding amount of interest. With his colleagues,
he has utilised protein microarray technology to screen
for 21 potential EV markers (including CD9, CD63
and CD81) in the blood of 80 healthy donors. When
comparing the expression of these surface markers on
EVs to the number of exosomes in the donors’ plasma,
they found that EVs from individuals with a lower
exosome count have a higher abundance of exosome
markers on their surface.
EV secretion is an evolutionary conserved feature, as
also demonstrated by many posters. Among data on EV
secretion by bacterial cells, the poster proposing a new
mechanism of antibiotics resistance conferred by EVs,
attracted significant interest. J. Lee, with his colleagues
(Pohang University of Science and Technology, Republic
ofKorea)studiedtheroleofStaphylococcusaureus-derived
EVs in inter-bacterial communication. By exposing
ampicillin-sensitive bacteria to EVs of ampicillin-resistant
bacteria, the authors found that the exposed bacteria
became insusceptible to the effects ampicillin. Since the
survival was transient and EVs did not contain the
resistance gene blaZ, this effect was most likely mediated
by the gene product itself, the beta-lactamase enzyme
presentinEVs.Furthermore,thereleaseofbeta-lactamase
containing EVs by resistant bacteria was enhanced in the
presence of ampicillin.
Beyond inter-bacterial communication, EVs might be
important in intercellular communication of a multi-
cellular organism as well, as demonstrated by A. Lo
Cicero and colleagues (Institut Curie, France). Within the
epidermal melanin unit, melanocytes supply keratino-
cytes with pigment melanin and keratinocytes provide
feedback to melanocytes. It has been known that soluble
mediators are involved in this feedback, but this work
places EVs in the model also. The results showing that
melanocytes isolated from Caucasian donors increase the
level of melanin in the presence of exosomes derived from
the keratinocytes of Black donors, clearly supports this
concept.
Uncovering the RNA content of EVs promises ther-
apeutic and diagnostic development, like RNA delivery
by EVs. In order to monitor this process, we need to track
both EVs and their cargo. C.P. Lai and his colleagues
(Massachusetts General Hospital, USA) described a
fluorescent reporter-based solution. They added a palmi-
toylation signal at the N-terminus of GFP or tdTomato
and then tagged the transcripts with MS2 RNA-binding
sequences. This way, the constructs were targeted to EV
membranes by the palmitoylation signal, as well as
capable of RNA binding. Whether RNA was actually
bound to the tagged protein, was detected by bacteri-
ophage MS2 coat protein fused to GFP. Using this
approach, co-localisation of EVs and their RNA cargo
could be demonstrated. Furthermore, simultaneous as-
sessment of the fate of EVs and RNA after uptake by
recipient cells also became possible.
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Hospital, Brazil) drew EV researchers’ attention to how
the over-expression of one single oncogene may alter
proteomic landscape of EVs. When comparing EVs of
HB4a human mammary luminal epithelial cell line and
its transformed clone over-expressing HER2, proteomic
analysis showed notable differences in the presence and
relative amount of proteins. Over-expression of HER2
resulted in both up- and down regulation of vesicular
proteins. This observation is very important when con-
sidering using constructs over-expressing a reporter, since
this may also affect the relative abundance of vesicular
proteins.
Loading EVs with nucleic acids, however, is therapeu-
tically even more promising than modifying the protein
content. A. Banizs and colleagues (University of Virginia,
USA) reported important results on the potential of
endothelial cell derived EVs as nucleic acid vectors. The
authors have provided comprehensive data on quality,
morphology and biodistribution of mouse aortic en-
dothelial exosomes. Additionally, it was also shown that
endothelial exosomes are able to bind to endothelial cells
and deliver functional siRNA into these cells, thus being
capable of nucleic acid delivery both in vitro and in vivo.
Furthermore, in another model system, mesenchymal
stem cell derived exosomes were found to be protective in
hypoxia induced pulmonary arterial hypertension (PAH)
by K. Sdrimas and colleagues (Children’s Hospital,
Boston, USA). Mesenchymal stem cell derived exosomes
were found to prevent remodelling of vascular smooth
muscle cells, triggered by hypoxia. The presence of exo-
somes inhibited the hypoxic activation of STAT3 and the
increase in a-smooth muscle actin (a-SMA) mRNA and
protein levels, as well as prevented the migration of lung
fibroblasts and counterbalanced the effects of PDGF on
vascular smooth muscle cells.
Another clinically relevant aspect of EV RNAs is their
role as potential biomarkers of various diseases. K
O’Brien and colleagues (Trinity College Dublin) have
thought a step ahead, and investigated the clinical
relevance of exosomal miRNAs in triple-negative breast
cancer. Exosomes were isolated from Hs578T breast
cancer cell line and its more invasive variant, Hs578Ts(i)8.
Analysis of RNAs present in EVs of the two cell lines,
suggests that tumour-related exosomal RNAs also have a
functional role beyond being mere markers of the disease.
The role of EVs in promoting tumour progression is
further supported by the results presented by T. Katsuda
and colleagues (National Cancer Center Research In-
stitute, Japan). Proposing a scenario, where osteosarcoma
exosomes educate the lung microenvironment in order to
enhance metastasis formation, the 143B human osteo-
sarcoma cell line was modified to lose the ability of
exosome secretion, by shRNA knockdown of neutral
sphyngomyelinase 2. When these cells were transplanted
to nude mice, tumour cells incapable of exosome secre-
tion developed a lung metastasis with a lower frequency
as compared to exosome secreting 143B cells. When 143B
derived exosomes were also administered to mice trans-
planted with 143B cells devoid of exosome secretion
capability, frequencies of lung metastasis were restored to
the original level. These results support that osteosarcoma-
derived exosomes enhance tumour progression by pre-
paring a pre-metastatic niche.
Concerning that EVs may promote tumour progres-
sion, it is also interesting whether EV dynamics are
altered during therapeutic intervention. This question
was addressed by K.A. Wong and colleagues (Tufts
Medical Center, USA), in a mouse model of glioblastoma
multiforme, characterised by the over-expression of
EGFR and impaired Cdkn2a function. In this system,
EGFR inhibition therapy resulted in differential sorting
of EV cargo, in parallel with an increased number of
tumour infiltrating microglia. Given that microglia were
shown to take up EVs derived from primary tumour cell
cultures, data presented here suggests that cargo altered
by the therapeutic intervention contributes to the forma-
tion of a different microenvironment.
M. Bu ¨rdek, with her colleagues (Fondazione IRCCS
Istituto Nazionale Tumori, Italy) focused on the role
of EVs in anti-tumour immunity. T cell reactivity to
melanoma cells derived exosomes was assessed by IFN-g
ELISPOT, cytokine release assay and detection of
activation markers (CD25 and CD137) by flow cytome-
try. HLA-A2, a key player in melanoma-specific immune
reaction, was also detected on exosomes derived from
HLA-A2 expressing cells and found to be important in
eliciting CD8 T cell response, as suggested by compari-
son of results with HLA-A2-restricted T cell clones and
oligoclonal cell lines. Although the nature of the immune
response against tumour derived EVs is still unclear, it is
very important to see that they do elicit T cell responses.
Further assessing immunological features linked to
EVs, M. Mossberg and colleagues (Lund University,
Sweden) focused on the role of EV in vasculitis. The
authors provided evidence on the presence of comple-
ment C3 and C9 on the surface of endothelial cell derived
microparticles in patients with vasculitis. Microparticles
were assessed by flow cytometry and endothelial origin
was determined by CD105 and CD144 staining. Patients
had significantly higher levels of endothelial microparti-
cles as compared to healthy controls, as well as higher
levels of both C9 and C3.
IV. Closing ceremony
During the ISEV 2013 closing, J. Lo ¨tvall and the Awards
Board of ISEV presented 14 young investigator awards
for outstanding poster presentations and 9 young in-
vestigator awards for outstanding oral presentation.
Elena Aikawa et al.
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presentations and 184 oral presentations.
The winners for outstanding poster presentations were
Vincent Hyenne, Jaewook Lee, Maria Amorim, Rikke
Baek, Charles Ping-Kuang-Lai, Katy Wong, Konstanti-
nos Sdrimas, Maria Mossberg, Maja Burdek, Kohei
Yuyama, Alessandra Lo Cicero, Keith O’Brien, Anna
Banizs, and Takeshi Katsuda.
The winners for outstanding oral presentations were
Stephen Biller, Stefania Bruno, Carolina Villarroya-
Beltri, Luis Ortiz, Thomas Wurdinger, Susmita Sahoo,
Aled Clayton, Muthuvel Jayachandran, and Esther
Nolte-’tHoen.
Next, a richly deserved ISEV Special Achievement
Award was presented to President J. Lo ¨tvall.
This was followed by the noting of meeting highlights
in the area of clinical applications as described by P.
Quesenberry and general highlights as described by M.
Wauben. Of the 427 abstracts, P. Quesenberry considered
101 as being of significant clinical interest. These included
many in the areas of solid and haematological cancers. In
addition, a significant number addressed neurologic
diseases such as Alzheimer’s and Parkinson’s. Miscella-
neous subjects of clinical interest included a study of
smoking, exosomes, and lung cancer; and the use of
photoactive vesicles for cancer therapy. P. Quesenberry
predicted that clinical trials with microvesicles will be a
critical feature of ISEV meetings within 23 years.
M. Wauben pointed out that many of the most im-
portant meeting highlights for her were comments that
she heard from scientists as she moved around the
meeting and attended the various poster sessions. The
posters, in fact, are ‘‘in the heart of our society,’’she said.
She provided some data to document the progress of the
society. The first international workshop in Paris in 2011
featured 115 abstracts and focused on exosomes. The
first ISEV Congress in 2012 featured 255 abstracts and
focused not only on exosomes, but also on microvesicles/
microparticles. This year’s ISEV Congress featured 427
abstracts and focused on exosomes, microvesicles, and
outer membrane vesicles from bacteria. This progress
came together with a significant increase in cross-talk
between and among different disciplines. One strong
message coming out of this year’s meeting, M. Wauben
said, is that microvesicles ‘‘offer a tremendous opportu-
nity for clinical applications.’’
Next, J. Lo ¨tvall announced that the site for the 2014
ISEV annual congress would be Rotterdam, The Nether-
lands in 2014 and scheduled to take place 30 April3
May 2014.
Finally, J. Lo ¨tvall and F. Hochberg declared that the
ISEV Boston 2013 meeting was finished.
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